The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic Targets
Open accessAbstract
Aberrant gene expression that drives human cancer can arise from epigenetic dysregulation. Although much attention has focused on altered activity of transcription factors and chromatin-modulating proteins, proteins that act posttranscriptionally can potently affect expression of oncogenic signaling proteins. The RNA-binding proteins (RBP) Musashi-1 (MSI1) and Musashi-2 (MSI2) are emerging as regulators of multiple critical biological processes relevant to cancer initiation, progression, and drug resistance. Following identification of Musashi as a regulator of progenitor cell identity in Drosophila, the human Musashi proteins were initially linked to control of maintenance of hematopoietic stem cells, then stem cell compartments for additional cell types. More recently, the Musashi proteins were found to be overexpressed and prognostic of outcome in numerous cancer types, including colorectal, lung, and pancreatic cancers; glioblastoma; and several leukemias. MSI1 and MSI2 bind and regulate the mRNA stability and translation of proteins operating in essential oncogenic signaling pathways, including NUMB/Notch, PTEN/mTOR, TGFβ/SMAD3, MYC, cMET, and others. On the basis of these activities, MSI proteins maintain cancer stem cell populations and regulate cancer invasion, metastasis, and development of more aggressive cancer phenotypes, including drug resistance. Although RBPs are viewed as difficult therapeutic targets, initial efforts to develop MSI-specific inhibitors are promising, and RNA interference–based approaches to inhibiting these proteins have had promising outcomes in preclinical studies. In the interim, understanding the function of these translational regulators may yield insight into the relationship between mRNA expression and protein expression in tumors, guiding tumor-profiling analysis. This review provides a current overview of Musashi as a cancer driver and novel therapeutic target. Clin Cancer Res; 23(9); 2143–53. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epithelial-Mesenchymal Transitions in Development and Disease
Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545
Cancerous stem cells can arise from pediatric brain tumors
Hemmati, H. D., Nakano, I., Lazareff, J. A., Masterman-Smith, M., Geschwind, D. H., Bronner-Fraser, M., & Kornblum, H. I. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2036535100 · Cited by 1,817
Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs
Oskarsson, T., Acharyya, S., Zhang, X. H.-F., Vanharanta, S., Tavazoie, S. F., Morris, P. G., Downey, R. J., Manova-Todorova, K., Brogi, E., & Massagué, J. (2011) · Nature Medicine · doi:10.1038/nm.2379 · Cited by 869
Mouse-Musashi-1, a Neural RNA-Binding Protein Highly Enriched in the Mammalian CNS Stem Cell
Sakakibara, S.-I., Imai, T., Hamaguchi, K., Okabe, M., Aruga, J., Nakajima, K., Yasutomi, D., Nagata, T., Kurihara, Y., Uesugi, S., et al. (1996) · Developmental Biology · doi:10.1006/dbio.1996.0130 · Cited by 526
Imai, T., Tokunaga, A., Yoshida, T., Hashimoto, M., Mikoshiba, K., Weinmaster, G., Nakafuku, M., & Okano, H. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3888-3900.2001 · Cited by 454
Wang, W., Whorton, M. R., & MacKinnon, R. (2014) · eLife · doi:10.7554/elife.03671 · Cited by 448
Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia
Kharas, M. G., Lengner, C. J., Al-Shahrour, F., Bullinger, L., Ball, B., Zaidi, S., Morgan, K., Tam, W., Paktinat, M., Okabe, R., et al. (2010) · Nature Medicine · doi:10.1038/nm.2187 · Cited by 379
Nakamura, M., Okano, H., Blendy, J. A., & Montell, C. (1994) · Neuron · doi:10.1016/0896-6273(94)90460-x · Cited by 358
Regulation of myeloid leukaemia by the cell-fate determinant Musashi
Ito, T., Kwon, H. Y., Zimdahl, B., Congdon, K. L., Blum, J., Lento, W. E., Zhao, C., Lagoo, A., Gerrard, G., Foroni, L., et al. (2010) · Nature · doi:10.1038/nature09171 · Cited by 355
Cited by
RNA-binding proteins in tumor progression
Qin, H., Ni, H., Liu, Y., Yuan, Y., Xi, T., Li, X., & Zheng, L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00927-w · Cited by 375
Alternative splicing and related RNA binding proteins in human health and disease
Tao, Y., Zhang, Q., Wang, H., Yang, X., & Mu, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01734-2 · Cited by 320
Nanomedicine-Based Approaches for mRNA Delivery
Uchida, S., Perche, F., Pichon, C., & Cabral, H. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00618 · Cited by 139
RNA-Targeted Therapies and High-Throughput Screening Methods
Zhu, S., Rooney, S., & Michlewski, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082996 · Cited by 41
Kairouani, A., Pontier, D., Picart, C., Mounet, F., Martinez, Y., Le-Bot, L., Fanuel, M., Hammann, P., Belmudes, L., Merret, R., et al. (2023) · eLife · doi:10.7554/elife.88207 · Cited by 7
Metadata
- Authors
- Kudinov, A. E., Karanicolas, J., Golemis, E. A., & Boumber, Y.
- Venue
- Clinical Cancer Research
- Published
- 2017-04-30
- Volume
- 23
- Issue
- 9
- Pages
- 2143-2153
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2584218507
- Cited by
- 262
- References
- 99
- FWCI
- 8.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic Targets. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-2728
- The paper
- Kudinov, A. E., Karanicolas, J., Golemis, E. A., & Boumber, Y. (2017). Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic Targets. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-2728
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.